1. Indications and Usage
\nALK-Positive Non-Small Cell Lung Cancer (NSCLC):
\nIndicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.
\nApproval Context:
\nTreatment-naive patients (first-line therapy).
\nPatients previously treated with one or more ALK tyrosine kinase inhibitors (TKIs).
\n2. Dosage and Administration
\nRecommended Dosage:
\n100 mg orally once daily.
\nAdministration Instructions:
\nAdminister orally with or without food.
\nSwallow tablets whole; do not crush, chew, or break.
\nDose Modifications:
\nDose reductions (to 75 mg or 50 mg once daily) are recommended based on individual safety and tolerability (e.g., for CNS effects, hyperlipidemia, or other severe adverse reactions).
\nIf the 50 mg dose is not tolerated, discontinue LORBRENA.
\n3. Mechanism of Action
\nALK and ROS1 Tyrosine Kinase Inhibitor:
\nLorlatinib is a macrocyclic, third-generation TKI that targets ALK and ROS1.
\nPhysiological Effect:
\nIt is designed to inhibit the proliferation of ALK- or ROS1 fusion-positive tumor cells.
\nIt is highly potent against various ALK resistance mutations (e.g., G1202R) and is engineered to effectively cross the blood-brain barrier to target central nervous system (CNS) metastases.
\n4. Safety and Warnings
\nCNS Effects:
\nLorlatinib can cause CNS effects, including cognitive, psychiatric, and speech disorders. Monitor for symptoms such as memory impairment, mood changes, or difficulty speaking.
\nHyperlipidemia:
\nElevations in cholesterol and triglycerides occur in the majority of patients. Monitor fasting lipid profile prior to initiation and periodically during treatment.
\nPulmonary Toxicity:
\nSevere and fatal cases of ILD\/non-infectious pneumonitis have been reported. Monitor for pulmonary symptoms (cough, dyspnea, hypoxia).
\nCardiac Toxicity:
\nBradycardia and atrioventricular (AV) block may occur. Monitor heart rate and blood pressure.
\nEmbryo-Fetal Toxicity:
\nCan cause fetal harm. Advise females of reproductive potential to use effective contraception.
\n5. Adverse Reactions
\nMost Common:
\nHyperlipidemia, CNS effects (peripheral neuropathy, cognitive effects, mood effects), weight gain, edema, diarrhea, nausea, fatigue, rash, and cough.
\n6. Drug Interactions
\nCYP3A Inducers:
\nConcomitant use with strong CYP3A inducers (e.g., rifampin) is contraindicated as it significantly decreases lorlatinib exposure.
\nCYP3A Inhibitors:
\nConcomitant use with strong CYP3A inhibitors increases lorlatinib exposure. Dose reduction should be considered.
\nCYP3A Substrates:
\nLorlatinib is a CYP3A inducer. Caution is advised when co-administering with CYP3A substrates.
\n7. Pharmaceutical Information
\nChemical Name:
\nN-(4-(2-amino-3,5-dimethylpyridin-4-yl)-2-fluorophenyl)-N-(prop-2-ynyl)cyclopropanecarboxamide.
\nStorage:
\nStore at 25\u00b0C (77\u00b0F); excursions permitted to 15-30\u00b0C (59-86\u00b0F).<\/p>\n","protected":false},"excerpt":{"rendered":"
Brand Name: \u535a\u745e\u7eb3 \u00ae(Lorbrena\u00ae)
\nGeneric Name: Lorlatinib
\nStrength: 100 mg per tablet, 30 tablets per box
\nManufacturer: Pfizer Manufacturing Deutschland GmbH
\nMarketing Authorization Holder: Pfizer Europe MA EEIG\uff1b\u5883\u5185\u6301\u8bc1\u4f01\u4e1a\uff1a\u8f89\u745e\u6295\u8d44\u6709\u9650\u516c\u53f8
\nApproval Date in China: April 29, 2022
\nRegistration Number: \u56fd\u836f\u51c6\u5b57 HJ20220041
\nStorage: Store below 30\u2103, keep tightly sealed, protect from light and moisture; keep out of sight and reach of children<\/p>\n
Price&Cost:Contact Us now for the best price of Lorlatinib\uff08Lorbrena\uff09<\/p>\n","protected":false},"featured_media":3143,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[81],"product_cat":[27],"product_tag":[],"class_list":["post-3142","product","type-product","status-publish","has-post-thumbnail","product_brand-pfizer","product_cat-tablets","first","instock","shipping-taxable","product-type-simple"],"yoast_head":"\n